Registering a participant for the Registry can be done following the process below.

1. The treating clinician approaches the Registry to notify of their plan to treat someone with TMS or other brain stimulation techniques. This can be done via email to tmsregistry.smp@anu.edu.au or via the website link here. You must obtain the patient’s consent. The referral should include the following:
   1. Patient’s full name and email address
   2. Referring doctors full name and email address
   3. Patient’s age
   4. Proposed treatment and indication
   5. Whether your patient has consented to be contacted by the Registry
2. The referral information of the person undergoing treatment is entered into the Registry, triggering an automated email with a link to the Participant Information and Consent Form (PICF).
   1. Individuals undergoing treatment will only be providing consent to participate in the Registry; consent in regard to the delivery of brain stimulation treatments will be the responsibility of the treating clinicians. Engagement in brain stimulation treatment will not be dependent on consenting to participate in the Registry.
3. If the participant consents, the treating clinician is emailed a link to commence the collection of the participant’s medical history, planned date/s for chosen therapy, and the short clinical global impression questionnaire (the participant will also receive a link to commence the collection of Registry data).
4. Both the treating clinician and the participant will be sent a series of questionnaires before, during, and after their proposed treatment, with a follow-up period of 15 months per treatment cycle (up to 4 cycles). Questionnaires for the treating clinician are very brief and collected less frequently than the participant’s questionnaires.

If you have any questions about this, you can contact the Registry at tmsregistry.smp@anu.edu.au.

Participants will be asked to complete online questionnaires at multiple timepoints. If your patient finishes a course of brain stimulation treatment and starts again (e.g., due to relapse of the condition), the follow-up period will start again from baseline. The schedule of data collection is as follows:

• Baseline
• Week 2 Follow Up (all based on treatment start date)
• Week 4 Follow Up
• Week 6 Follow Up
• Week 8 Follow Up
• Week 10 Follow Up
• 3-Month Follow Up
• 6-Month Follow Up
• 9-Month Follow Up
• 12-Month Follow Up
• 15-Month Follow Up

Not all questionnaires are completed at every timepoint due to the time burden; however, they are all completed at points before, during, and after treatment. The questionnaires are:

1. Patient Health Questionnaire 9 (PHQ-9)
2. Generalised Anxiety Disorder Assessment 7 (GAD-7)
3. Depression, Anxiety and Stress Scale 21 (DASS-21)
4. Assessment of Quality of Life 8D (AQoL-8D)
5. Side effects questionnaire

Communication of Results

If your patient consents, you will be sent your patients outcome results via email at week 10 and the end of a treatment cycle.